|Description||OPC 31260 is a Vasopressin receptor antagonist marketed by Otsuka. It is a benzazepine derivative that antagonizes the binding of arginine vasopressin (AVP) to vasopressin receptors located in the liver (V1; IC50 = 1.2 µM) and kidney (V2; IC50 = 14 nM). In Japan, OPC 31260 was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.|
|Appearance||white to tan powder|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Otsuka Pharmaceutical|
Conivaptan HCl is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist).
Desmopressin acetate, a syntheticpeptide containing nine amino acids, is analogue of the antidiuretic hormone arginine vasopressin. Improves hemostatsis by incr...
This molecular is a polypeptide which is a Antidiuretic hormone that has been found in most mammalian species and it acts as a neurotransmitter at synapses in t...
OPC 31260 hydrochloride
OPC 31260 is a Vasopressin receptor antagonist marketed by Otsuka. It is a benzazepine derivative that antagonizes the binding of arginine vasopressin (AVP) to ...
Felypressin is a Vasopressin 1 agonist and has effects at all Arginine vasopressin receptor 1As. It is a non-catecholamine vasoconstrictor that is chemically re...
Conivaptan, also called as YM 087 or Vaprisol, is the first is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist) approved by Un...
Ribuvaptan is a vasopressin receptor antagonist originated by Bayer HealthCare Pharmaceuticals. Now, Ribuvaptan is still in phase I development for the treatmen...
Desmopressin (DDAVP) Acetate, a synthetic analog of the endogenous antidiuretic hormone arginine vasopressin with low vasopressor activity, is a dual antagonist...
VPA-985, an azepine compound, has been found to be a Vasopressin receptor antagonist that could be used in some cardiovascular disease therapy like hyponatraemi...
Fedovapagon is a potent, nonpeptidic vasopressin V2 receptor agonists (EC50 of 24 nM), demonstrated positive anti-diuretic effect in nocturia
Tolvaptan is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.